Presentation on theme: "Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David."— Presentation transcript:
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David Antoniucci on behalf of the JETSTENT Investigators
JETSTENT TRIAL Steering Committe: D Antoniucci (PI), A Colombo (PI), F-J Neumann, A Rodriguez, A Stabile, J Gustafson Data monitoring and management and Core Labs: MCR (EKG, Angio), Florence University (Nuclear) Clinical event adjudication committee: GB Danzi (I), C Di Mario (UK), and I Moussa (USA) Country sites: Italy (4); Argentina (1); Germany (1); Poland (3). Sponsor: Medrad Interventional/Possis
After angiography and IRA wiring: thrombus grade 3 to 5 Randomization 1:1 Pts with STEMI admitted within 12 hours from symptom onset Lysis Stroke < 30 days Surgery < 6 weeks Pre-stented IRA Rheolytic Thrombectomy +DSDirect Stenting (DS) Study Design N = 500
JETSTENT TRIAL Primary surrogate end points: Early ST-segment resolution (≥ 50% ST segment elevation reduction at 30 minutes) Infarct size (1-month 99m Tc sestamibi scintigraphy) Clinical end points: MACCE at 1, 6, and 12 months, Death and Readmission for HCF at 12 months Secondary surrogate end points: TIMI flow, cTFC, and TIMI blush
Conclusions Rheolytic thrombectomy before direct IRA stenting as compared to direct IRA stenting alone is associated with a better myocardial reperfusion (higher early ST-segment resolution rate) and 6-month clinical outcome (lower MACCE rate). The results of the JETSTENT trial support the routine use of rheolytic thrombectomy in STEMI patients with evidence of thrombus.